- Open Access
Feasibility of constant dose rate VMAT in the treatment of nasopharyngeal cancer patients
© Yu et al.; licensee BioMed Central Ltd. 2014
Received: 16 July 2014
Accepted: 12 October 2014
Published: 4 November 2014
To investigate the feasibility of constant dose rate volumetric modulated arc therapy (CDR-VMAT) in the treatment of nasopharyngeal cancer (NPC) patients and to introduce rotational arc radiotherapy for linacs incapable of dose rate variation.
Materials and methods
Twelve NPC patients with various stages treated previously using variable dose rate (VDR) VMAT were enrolled in this study. CDR-VMAT, VDR-VMAT and mutlicriteria optimization (MCO) VMAT plans were generated for each patient on RayStation treatment planning system with identical objective functions and the dosimetric differences among these three planning schemes were evaluated and compared. Non dosimetric parameters of optimization time, delivery time and delivery accuracy were also evaluated.
The planning target volume of clinical target volume (PTV-CTV) coverage of CDR-VMAT was a bit inferior to those of VDR- and MCO-VMAT. The V93 (p = 0.01) and V95 (percent volume covered by isodose line) (p = 0.04) for CDR-VMAT, VDR-VMAT and MCO-VMAT were 98.74% ± 0.31%, 99.76% ± 0.16%, 99.38% ± 0.43%, and 98.40% ± 0.48%, 99.53% ± 0.28%, 99.07% ± 0.52%, respectively. However, the CDR-VMAT showed a better dose homogeneity index (HI) (p = 0.01) in PTV-CTV. No significant difference in other target coverage parameters was observed. There was no significant difference in OAR sparing among these three planning schemes except for a higher maximum dose (Dmax) on the brainstem for CDR-VMAT. The brainstem Dmax of CDR-VMAT, VDR-VMAT and MCO-VMAT were 54.26 ± 3.21 Gy, 52.19 ± 1.65 Gy, and 52.79 ± 4.77 Gy, respectively. The average delivery time (p < 0.01) and the average percent γ passing rates (p = 0.02) of CDR-VMAT, VDR-VMAT and MCO-VMAT were 7.01 ± 0.43 min, 4.75 ± 0.07 min, 4.01 ± 0.28 min, and 95.75% ± 2.57%, 97.65% ± 1.45%, 97.36% ± 2.45%, respectively.
CDR-VMAT offers an additional option of rotational arc radiotherapy for linacs incapable of dose rate variation with a lower initial cost. Its plan quality was acceptable but should be thoroughly checked compared with VDR-VMAT and MCO-VMAT in the treatment of NPC.
Due to its dose painting ability, intensity-modulated radiation therapy (IMRT), which is able to deliver more conformal radiation to the tumor than earlier techniques and spare the surrounding normal tissue from unnecessary exposure , has been accepted as a standard treatment modality for nasopharyngeal cancer (NPC) . Disadvantages of IMRT are the longer required irradiation time and the greater total number of monitor units (MUs) compared with conventional methods . The increased irradiation time may increase the intrafractional error and the patient restriction time. Additionally, an increase in the total number of MUs may expose the patients to the risk of low-dose irradiation owing to increased leakage .
More recently, volumetric-modulated arc therapy (VMAT), an extended form of IMRT using a variable dose rate (VDR), dynamic gantry speed and multileaf collimator (MLC) field shape, has gained considerable attention . VMAT plans with shorter delivery time, fewer MU, and superior or equivalent plan quality compared to conventional step-and-shoot IMRT have been reported for prostate cancer and NPC ,. However, to use the VMAT approach, the hardware and software systems of the radiation treatment planning system (TPS), as well as the linear accelerator (linac), must be upgraded. These upgrades are costly. Thus, many institutions do not have the means to perform VMAT and must continue with the problems specified above. Constant dose rate (CDR) VMAT is a rotational IMRT technique that uses a fixed gantry rotational speed and a fixed dose rate. Compared with fixed field IMRT, the potential advantages of CDR with a great reduction in irradiation time and clinical acceptable dose distribution has been reported ,. For institutions that do not currently perform VDR-VMAT, CDR-VMAT may be a useful option.
Multicriteria optimization (MCO) with multipareto fronts has emerged as a tool for comparing treatment plans as it gives better visualization of the trade-offs -. MCO allows trade-offs between conflicting objectives encountered in VMAT planning to be explored in an interactive manner through search over a continuous representation of the relevant treatment options. MCO-VMAT plans in the treatment of prostate, pancreas, lung, and head and neck cancer patients have been reported with comparable dose distribution quality to conventionally optimized VMAT plans . During the MCO optimization process, despite protocols, the final choice of the best solution will be planner dependent. However, in comparing Pareto fronts for different techniques, a bias towards planner experience can be minimized.
NPC is the most common H&N malignancy in Southeast Asia and China. The newly VDR-VMAT is an ideal treatment technique in NPC treatment but cost too much in linac upgrading. The purpose of this study is to investigate the dosimetric differences among CDR-VMAT, VDR-VMAT and MCO-VMAT and the feasibility of CDR-VMAT in the treatment of NPC patients.
Materials and methods
Patients and contours
Twelve patients with various stages of NPC treated previously by VDR-VMAT were enrolled in this study. All VDR-VMAT plans with initial CT data were exported from the Pinnacle TPS to the Raystation TPS (clinical version 3.5, RaySearch Laboratories, Stockholm, Sweden) through the DICOM service and the dose distributions were recalcuated based on the same CT number to density calibration curve using a collapsed cone dose engine with a dose grid of 4 mm ± 4 mm ± 4 mm. CDR-VMAT, VDR-VMAT and MCO-VMAT plans were generated for each patient on the RayStation TPS. The Raystation TPS was commissioned with the same beam data as the Pinnacle system. The dose deviations between Raystation and Pinnacle were within 1.5% during the commission process. Dosimetric differences among these three planning methods were compared.
Objective setting and weight for inverse optimization
Max EUD A1
Max EUD A1
1 cm Ring out CTV
For MCO optimization, the Pareto surface was approximated by using N +1 treatment plans, where N is the number of objectives. N of the plans are from each of the objectives being minimized individually. The additional plan is a balanced plan formed by optimizing the equal weighted sum of all objectives. A senior physician will navigating the base plans and decided the best plan. When navigation is completed, the Raystation TPS will create a deliverable version of the selected plan by a direct aperture optimization algorithm using a total of 50 segments as VDR-VMAT and CDR-VMAT to match the navigated DVH.
Plan evaluation and comparison
The dose distributions delivered by the three modalities were compared by evaluating target coverage (TC) and OAR sparing. The maximum dose (Dmax), minimum dose (Dmin), mean dose (Dmean), the volumes receiving 93% (V93) and 95% (V95) of the prescribed dose of PTV-GTV and PTV-CTV; the Dmax of brainstem, spinal cord, lens, and the Dmean of parotids were evaluated and compared. For parotids, the percent volume of each parotid that received 26 Gy (V26), and 32 Gy (V32) was also evaluated and compared. Additional quality indices were calculated for further evaluation and comparison as listed in the following paragraphs.
Where VT,Pi is the volume of the target that is covered by the prescription dose, VT is the target volume. VPi is the volume of the body that is covered by the prescription isodose. The maximum value of the CI is 1, corresponding to a perfect coverage of the PTV. The CN is the complementary information to compensate for the defects of target coverage and CI. The CN can take values between 0 and 1, where an ideal dose distribution would have a CN value of 1.
The VMAT plans were verified by an ArcCheck phantom and the SNCP Patient analysis software (Version 6, Sun Nuclear Corporation, Melbourne, FL) with a gamma criterion of 3%/ 3 mm. For profile analysis, a threshold dose of 10% of the maximum dose was used. All plans were delivered on an Elekta Synergy linac (Elekta Ltd., Crawley, UK) with a MOSAIQ record and verify system (version 1.60Q3, IMPAC Medical Systems, Inc.,Sunnyvale, CA). Besides, the optimization time, MU efficiency, and delivery time were compared.
The differences among the three planning schemes were analyzed using one-way ANOVA. When an overall significant difference was observed, the post hoc Turkey's test was used to determine which pair-wise comparisons differed. All statistical analyses were conducted with the SPSS 17.0 software. Differences were considered statistically significant for p <0.05.
PTC-CTV volume (cm3)
PTV-GTV volume (cm3)
Target coverage comparison
68.41 ± 1.21
68.71 ± 1.28
68.34 ± 0.47
71.02 ± 0.93
70.66 ± 1.29
70.44 ± 0.63
99.91 ± 0.18
99.93 ± 0.04
99.98 ± 0.02
99.72 ± 0.38
99.69 ± 0.13
99.83 ± 0.16
0.11 ± 0.021
0.12 ± 0.016
0.11 ± 0.026
0.62 ± 0.64
0.57 ± 0.10
0.65 ± 0.06
0.62 ± 0.44
0.56 ± 0.11
0.63 ± 0.05
56.65 ± 0.47
57.50 ± 1.08
56.15 ± 0.62
70.09 ± 0.83
70.76 ± 1.06
70.57 ± 0.43
98.74 ± 0.31
99.76 ± 0.16
99.38 ± 0.43
98.40 ± 0.48
99.53 ± 0.28
99.07 ± 0.52
0.28 ± 0.017
0.29 ± 0.012
0.31 ± 0.023
0.58 ± 0.14
0.57 ± 0.10
0.60 ± 0.06
0.58 ± 0.04
0.56 ± 0.12
0.57 ± 0.15
OAR sparing comparison
54.26 ± 3.21
52.19 ± 1.65
52.79 ± 4.77
45.12 ± 4.94
44.59 ± 2.10
44.11 ± 4.37
29.72 ± 1.48
28.42 ± 1.75
28.46 ± 2.70
53.84 ± 4.41
50.55 ± 3.75
49.73 ± 8.82
34.36 ± 5.50
33.22 ± 5.28
33.01 ± 9.33
6.44 ± 5.05
6.55 ± 5.65
5.72 ± 4.58
29.79 ± 1.73
28.76 ± 1.15
28.6 ± 2.18
48.04 ± 3.90
47.38 ± 3.75
48.45 ± 7.99
31.78 ± 5.80
30.22 ± 5.35
30.84 ± 8.28
7.07 ± 3.81
6.17 ± 3.93
6.26 ± 3.34
This study has investigated the dosimetric differences among CDR-VMAT, VDR-VMAT and MCO-VMAT in the treatment of NPC patients and the feasibility of CDR-VMAT. Dual arc CDR-VMAT is able to achieve acceptable target coverage and OAR sparing compared with VDR-VMAT and MCO-VMAT in the treatment of NPC patients.
Due to the limited availability of linacs with reliable variable dose rate capability, CDR-VMAT has been investigated in order to deliver rotational arcs using a constant dose-rate with a lower initial cost compared with VDR-VMAT . In this study, CDR-VMAT achieves a similar target coverage, dose homogeneity and conformity of the PTV-GTV compared with VDR-VMAT and MCO-VMAT. However, CDR-VMAT was a bit inferior on the coverage on PTV-CTV and superior in dose homogeneity. Similar results have been reported, showing that the differences in the GTV and PTV coverage for head-and-neck cancer patients (dose received by 95% of GTV or PTV) in the VDR- and CDR-VMAT plans were within 0.1% . The maximum dose to the brainstem for CDR-VMAT was a bit higher compared with the other two planning schemes, but it was still within the clinical tolerance. There was no other significant difference on OAR sparing among these three VMAT planning schemes.
MCO with a pareto surface-based technique has been demonstrated as a method to efficiently explore tradeoffs between different treatment goals in the irradiation of various tumors. Treatment plans selected from such a representation are of comparable dose distribution quality to conventionally optimized VMAT plans . In this study, consistent results were observed with equivalent dose distribution for MCO-VMAT and VDR-VMAT in the treatment of NPC. The equivalent dosimetric distribution of CDR-VAMT was further verified by MCO-VMAT in this study.
The delivery efficiency and MU reduction are some of the features that VMAT was favored over conventional fixed field IMRT. The average delivery time of CDR-VMAT was longer than VDR-VMAT (7.01 ± 0.43 min vs. 4.75 ± 0.07 min), but it was still much shorter than that of IMRT (11.01 ± 0.43 min) as reported in our previous study . All the CDR-VMAT plans were delivered smoothly and accurately in this study with an average percent γpassing rate of 95.75% ± 2.57%. This is consistent with the study of Tang et al. 
VDR-VMAT both with single arc and dual arc has been widely investigated in the treatment of various tumor sites with superior or equivalent dose distribution and reduced delivery time and MUs ,,. However, the VDR-VMAT capability is not available for the low- or intermediate-end linacs without upgrade in institutions especially in the underdeveloped countries and regions. A careful study in the dosimetric distribution and feasibility of CDR-VMAT in such institutions will be of clinical benefit for both hospitals and patients.
CDR-VMAT offers an additional option of rotational arc radiotherapy for linacs incapable of dose rate variation with a lower initial cost. Its plan quality is acceptable but should be checked with care compared to VDR-VMAT and MCO-VMAT in the treatment NPC.
The study was supported by a grant from the Wenzhou Science and Technology Bureau (H20100068).
- Pirzkall A, Carol M, Lohr F, Höss A, Wannenmacher M, Debus J: Comparison of intensity modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys. 2000, 48: 1371-1380. 10.1016/S0360-3016(00)00772-0.View ArticlePubMedGoogle Scholar
- Lee N, Kramer A, Xia P: A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) t/_ Chemotherapy for Nasopharyngeal Cancer. 2003, Radiation Therapy Oncology Group, Philadelphia, PAGoogle Scholar
- Ruben JD, Lancaster CM, Jones P, Smith RL: A comparison of out-of-field dose and its constituent components for intensity-modulated radiation therapy versus conformal radiation therapy: implications for carcinogenesis. Int J Radiat Oncol Biol Phys. 2011, 81: 1458-1464. 10.1016/j.ijrobp.2010.08.008.View ArticlePubMedGoogle Scholar
- Otto K: Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008, 35: 310-317. 10.1118/1.2818738.View ArticlePubMedGoogle Scholar
- Palma D, Vollans E, James K, Nakano S, Moiseenko V, Shaffer R, McKenzie M, Morris J, Otto K: Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2008, 72: 996-1001. 10.1016/j.ijrobp.2008.02.047.View ArticlePubMedGoogle Scholar
- Jin X, Yi J, Zhou Y, Yan H, Han C, Xie C: Comparing of whole-field simultaneous integrated boost VMAT and IMRT in the treatment of nasopharyngeal cancer. Med Dosim. 2013, 38: 418-423. 10.1016/j.meddos.2013.05.004.View ArticlePubMedGoogle Scholar
- McGarry CK, McMahon SJ, Craft D, O'Sullivan JM, Prise KM, Hounsell AR: Inverse planned constant dose rate volumetric modulated arc therapy (VMAT) as an efficient alternative to five-field intensity modulated radiation therapy (IMRT) for prostate. J Radiother Pract. 2014, 13: 68-78. 10.1017/S1460396913000083.View ArticleGoogle Scholar
- Ottosson RO, Engstrom PE, Sjöström D, Behrens CF, Karlsson A, Knöös T, Ceberg C: The feasibility of using Pareto fronts for comparison of treatment planning systems and delivery techniques. Acta Oncol. 2009, 48: 233-237. 10.1080/02841860802251559.View ArticlePubMedGoogle Scholar
- Petersson K, Ceberg C, Engstrom P, Benedek H, Nilsson P, Knoos T: Conversion of helical tomotherapy plans to step-and-shoot IMRT plans-Pareto front evaluation of plans from a new treatment planning system. Med Phys. 2011, 38 (6): 3130-3138. 10.1118/1.3592934.View ArticlePubMedGoogle Scholar
- Craft D, Halabi T, Bortfeld T: Exploration of tradeoffs in intensity-modulated radiotherapy. Phys Med Biol. 2005, 50: 5857-5868. 10.1088/0031-9155/50/24/007.View ArticlePubMedGoogle Scholar
- Bokrantz R: Multicriterial optimization for volumetric-modulated arc therapy by decomposition into a fluence-based relaxation and a segment weight-based restriction. Med Phys. 2012, 39: 6712-6725. 10.1118/1.4754652.View ArticlePubMedGoogle Scholar
- Wu S, Xie C, Jin X, Zhang P: Simultaneous modulated accelerated radiation therapy in the treatment of nasopharyngeal cancer: a local center's experience. Int J Radiat Oncol Biol Phys. 2006, 66: S40-S46. 10.1016/j.ijrobp.2005.12.041.View ArticleGoogle Scholar
- Iori M, Cattaneo GM, Cagni E, Fiorino C, Borasi G, Riccardo C, Iotti C, Fazio F, Nahum AE: Dose-volume and biological-model based comparison between helical tomotherapy and (inverse-planned) IMAT for prostate tumours. Radiother Oncol. 2008, 88: 34-45. 10.1016/j.radonc.2008.03.003.View ArticlePubMedGoogle Scholar
- Lomax NJ, Scheib SG: Quantifying the degree of conformity in radiosurgery treatment planning. Int J Radiat Oncol Biol Phys. 2003, 55: 1409-1419. 10.1016/S0360-3016(02)04599-6.View ArticlePubMedGoogle Scholar
- van’t Riet A, Mak AC, Moerland MA, Elders LH, van der Zee W: A conformation number to quantify the degree of conformity in brachytherapy and external beam irradiation: application to the prostate. Int J Radiat Oncol Biol Phys. 1997, 37: 731-736. 10.1016/S0360-3016(96)00601-3.View ArticlePubMedGoogle Scholar
- Hatanaka S, Tamaki S, Endo H, Mizuno N, Nakamura N: Utility of Smart Arc CDR for intensity-modulated radiation therapy for prostate cancer.J Radiation Res 2014, pp 1-6, doi: 10.1093/jrr/rrt232.,Google Scholar
- Tang G, Earl MA, Yu CX: Variable dose rate single-arc IMAT delivered with a cosntant dose rate and variable angular spacing. Phys Med Biol. 2009, 54: 6439-6456. 10.1088/0031-9155/54/21/001.View ArticlePubMedGoogle Scholar
- Popescu CC, Olivotto IA, Beckham WA, Ansbacher W, Zavgorodni S, Shaffer R, Wai ES, Otto K: Volumetric modulatedarc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left- sided breast cancer and internal mammary nodes. Int J Radiat Oncol Biol Phys. 2010, 76: 287-295. 10.1016/j.ijrobp.2009.05.038.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.